NVS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz...

Stats
Šios dienos apimtis	1.46M
Vidutinė apimtis	1.63M
Rinkos kapitalizacija	190.64B
EPS	$0 ( 2024-04-23 )
Kita pelno data	( $1.850 ) 2024-07-16
Last Dividend	$3.47 ( 2023-03-09 )
Next Dividend	$0 ( N/A )
P/E	22.15
ATR14	$0.0230 (0.02%)

Tūris Koreliacija

Ilgas: -0.67 (moderate negative)

Trumpas: -0.82 (strong negative)

Signal:(23.382) Be Aware. Possible trading coming up! (swing)

Novartis AG Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Novartis AG Koreliacija - Valiuta/Žaliavos

-0.04
( neutral )

0.12
( neutral )

0.00
( neutral )

-0.40
( neutral )

-0.19
( neutral )

-0.51
( weak negative )

Novartis AG Finansinės ataskaitos

Annual	2023
Pajamos:	$46.66B
Bruto pelnas:	$34.19B (73.27 %)
EPS:	$7.15

FY	2023
Pajamos:	$46.66B
Bruto pelnas:	$34.19B (73.27 %)
EPS:	$7.15

FY	2022
Pajamos:	$51.83B
Bruto pelnas:	$36.34B (70.12 %)
EPS:	$3.19

FY	2021
Pajamos:	$52.88B
Bruto pelnas:	$37.01B (69.99 %)
EPS:	$10.71

Financial Reports:

No articles found.

Novartis AG Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$3.47 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Novartis AG Dividend Information - Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.42 - Stable (8.45%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.966	2000-11-14
Last Dividend	$3.47	2023-03-09
Next Dividend	$0	N/A
Payout Date	2023-03-20
Next Payout Date	N/A
# dividends	23	--
Total Paid Out	$44.60	--
Avg. Dividend % Per Year	2.46%	--
Score	4.08	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.42
Div. Directional Score	7.88	--

Next Divdend (Est)
(2025-01-10)

$0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

4.08

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2000	$0.966	2.96%
2001	$0.450	1.12%
2002	$0.468	1.46%
2003	$0.627	1.89%
2004	$0.722	1.57%
2005	$0	0.00%
2006	$0.801	1.50%
2007	$0.969	1.67%
2008	$1.319	2.42%
2009	$1.541	3.11%
2010	$1.780	3.38%
2011	$2.11	3.56%
2012	$2.20	3.78%
2013	$2.27	3.56%
2014	$2.44	3.10%
2015	$2.52	2.73%
2016	$2.47	2.88%
2017	$2.46	3.38%
2018	$2.67	3.15%
2019	$2.57	3.06%
2020	$3.04	3.20%
2021	$3.38	3.58%
2022	$3.36	3.82%
2023	$3.47	3.76%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
VGI	Dividend Royal	2024-02-09	Monthly	13	7.36%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50
PDI	Dividend Royal	2023-11-10	Monthly	13	7.86%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.307	1.500	3.86	5.79	[0 - 0.5]
returnOnAssetsTTM	0.162	1.200	4.61	5.54	[0 - 0.3]
returnOnEquityTTM	0.346	1.500	7.27	10.00	[0.1 - 1]
payoutRatioTTM	0.342	-1.000	6.58	-6.58	[0 - 1]
currentRatioTTM	0.903	0.800	-0.485	-0.388	[1 - 3]
quickRatioTTM	0.613	0.800	-1.102	-0.881	[0.8 - 2.5]
cashRatioTTM	0.323	1.500	9.31	10.00	[0.2 - 2]
debtRatioTTM	0.273	-1.500	5.45	-8.17	[0 - 0.6]
interestCoverageTTM	12.32	1.000	6.55	6.55	[3 - 30]
operatingCashFlowPerShareTTM	6.73	2.00	7.76	10.00	[0 - 30]
freeCashFlowPerShareTTM	4.96	2.00	7.52	10.00	[0 - 20]
debtEquityRatioTTM	0.649	-1.500	7.40	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.726	1.000	1.237	1.237	[0.2 - 0.8]
operatingProfitMarginTTM	0.219	1.000	7.61	7.61	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.534	1.000	8.14	8.14	[0.2 - 2]
assetTurnoverTTM	0.526	0.800	9.83	7.86	[0.5 - 2]
Total Score				10.33

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	13.06	1.000	8.78	0	[1 - 100]
returnOnEquityTTM	0.346	2.50	8.24	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	4.96	2.00	8.35	10.00	[0 - 30]
dividendYielPercentageTTM	3.88	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.73	2.00	7.76	10.00	[0 - 30]
payoutRatioTTM	0.342	1.500	6.58	-6.58	[0 - 1]
pegRatioTTM	-3.02	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.277	1.000	5.57	0	[0.1 - 0.5]
Total Score				5.42

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.